Shanghai HeartCare Medical Technology Full Year 2023 Earnings: Misses Expectations

Shanghai HeartCare Medical Technology (HKG:6609) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥232.3m (up 27% from FY 2022).
• Net loss: CN¥94.0m (loss narrowed by 53% from FY 2022).
• CN¥2.47 loss per share (improved from CN¥5.24 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai HeartCare Medical Technology Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 79%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 1.6% from a week ago.

Risk Analysis

Be aware that Shanghai HeartCare Medical Technology is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.